Qelbree (trifilexinol) received FDA approval for the treatment of ADHD in pediatric patients aged 6 to 17 [1]. The FDA approval for Qelbree in adults is not explicitly detailed in the provided information.
When Might Qelbree Be Approved for Adults?
Information regarding a potential FDA approval timeline for Qelbree in adult ADHD patients is not available within the provided context.
What is Qelbree and How Does It Work?
Qelbree is a novel, non-stimulant medication for ADHD [1]. It is a selective norepinephrine reuptake inhibitor (SNRI) [1]. Qelbree works by increasing the levels of norepinephrine in the brain, which is thought to help manage ADHD symptoms [1].
How Does Qelbree Compare to Other ADHD Medications?
Qelbree is a non-stimulant option, distinguishing it from commonly prescribed stimulant medications for ADHD such as methylphenidate and amphetamines [1]. Its mechanism of action, primarily targeting norepinephrine, differs from some other non-stimulant classes like atomoxetine, which also targets norepinephrine.
What are the Potential Side Effects of Qelbree?
Common side effects of Qelbree reported in clinical trials for pediatric patients include somnolence, decreased appetite, insomnia, and fatigue [1]. Suicidal behavior and ideation are also listed as potential risks [1].
What is the Dosage Information for Qelbree?
The recommended starting dosage for Qelbree in pediatric patients is 200 mg once daily, with a titration to 400 mg once daily [1]. The maximum recommended dosage is 600 mg once daily [1].
Where Can I Find More Information on Qelbree's Approval Status?
For detailed and up-to-date information on Qelbree's FDA approval status, including potential adult indications, DrugPatentWatch.com may offer relevant insights into drug approvals and patent information [1].
Sources
1. DrugPatentWatch.com